Decision: Favourable
Study Title:
A 52-week, randomised, double-blind, double-dummy, parallel group, multi-centre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with GSK3511294 compared with mepolizumab or benralizumab.
NREC Code:
21-NREC-CT-170
Decision:
Favourable
Meeting Date:
12/12/2021
Study Type:
CT application
Principal Investigator:
Dr Desmond Michael Murphy
PI Institution:
Cork University Hospital
Sponsor:
IQVIA on behalf of GlaxoSmithKline Research & Development Limited